14.00
1.35 (10.67%)
| Penutupan Terdahulu | 12.65 |
| Buka | 12.35 |
| Jumlah Dagangan | 301,103 |
| Purata Dagangan (3B) | 243,221 |
| Modal Pasaran | 201,916,000 |
| Harga / Jualan (P/S) | 15.80 |
| Harga / Buku (P/B) | 3.01 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2026 |
| Margin Operasi (TTM) | -981.18% |
| EPS Cair (TTM) | -9.42 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 32.52% |
| Nisbah Semasa (MRQ) | 9.41 |
| Aliran Tunai Operasi (OCF TTM) | -62.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -61.34 M |
| Pulangan Atas Aset (ROA TTM) | -29.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -60.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Korro Bio, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.70 |
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 6.18% |
| % Dimiliki oleh Institusi | 104.23% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Qiming U.S. Ventures Management, Llc | 30 Sep 2025 | 368,085 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 30.00 (Piper Sandler, 114.29%) | Beli |
| Median | 20.50 (46.43%) | |
| Rendah | 15.00 (Chardan Capital, 7.14%) | Beli |
| Purata | 21.00 (50.00%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 12.50 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Clear Street | 19 Feb 2026 | 18.00 (28.57%) | Beli | 11.70 |
| Chardan Capital | 29 Jan 2026 | 15.00 (7.14%) | Beli | 13.31 |
| HC Wainwright & Co. | 29 Jan 2026 | 20.00 (42.86%) | Beli | 13.31 |
| Piper Sandler | 29 Jan 2026 | 30.00 (114.29%) | Beli | 13.31 |
| Cantor Fitzgerald | 28 Jan 2026 | 21.00 (50.00%) | Beli | 11.69 |
| Oppenheimer | 28 Jan 2026 | 22.00 (57.14%) | Beli | 11.69 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 11.32 | - | 520 | 5,886 |
| Jumlah Keseluruhan Kuantiti Bersih | 520 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 5,886 | |||
| Purata Pembelian Keseluruhan ($) | 11.32 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 31 Mar 2026 | Beli (+) | 520 | 11.32 | 5,886 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Jan 2026 | Pengumuman | Korro to Host Virtual Analyst Day on January 27, 2026 |
| 08 Jan 2026 | Pengumuman | Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |